NASDAQ:FREQ

Frequency Therapeutics Competitors

$9.67
+0.13 (+1.36 %)
(As of 04/21/2021 01:11 PM ET)
Add
Compare
Today's Range
$9.35
Now: $9.67
$9.81
50-Day Range
$7.99
MA: $22.62
$48.00
52-Week Range
$7.34
Now: $9.67
$58.37
Volume18,021 shs
Average Volume1.23 million shs
Market Capitalization$330.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.69

Competitors

Frequency Therapeutics (NASDAQ:FREQ) Vs. ENDP, SAVA, STTK, ZYME, INVA, and CMPS

Should you be buying FREQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Frequency Therapeutics, including Endo International (ENDP), Cassava Sciences (SAVA), Shattuck Labs (STTK), Zymeworks (ZYME), Innoviva (INVA), and COMPASS Pathways (CMPS).

Endo International (NASDAQ:ENDP) and Frequency Therapeutics (NASDAQ:FREQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Endo International and Frequency Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Endo International23302.13
Frequency Therapeutics00303.00

Endo International currently has a consensus price target of $7.6667, suggesting a potential upside of 33.10%. Frequency Therapeutics has a consensus price target of $37.00, suggesting a potential upside of 282.63%. Given Frequency Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Frequency Therapeutics is more favorable than Endo International.

Profitability

This table compares Endo International and Frequency Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Endo International-5.30%-85.80%7.19%
Frequency Therapeutics-68.59%-12.56%-9.92%

Volatility & Risk

Endo International has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Frequency Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Earnings & Valuation

This table compares Endo International and Frequency Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Endo International$2.91 billion0.45$-422,640,000.00$2.382.42
Frequency Therapeutics$28.95 million11.42$-18,750,000.00($2.29)-4.22

Frequency Therapeutics has lower revenue, but higher earnings than Endo International. Frequency Therapeutics is trading at a lower price-to-earnings ratio than Endo International, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

80.0% of Endo International shares are held by institutional investors. Comparatively, 57.5% of Frequency Therapeutics shares are held by institutional investors. 1.5% of Endo International shares are held by company insiders. Comparatively, 15.4% of Frequency Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Endo International beats Frequency Therapeutics on 7 of the 13 factors compared between the two stocks.

Frequency Therapeutics (NASDAQ:FREQ) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Frequency Therapeutics and Cassava Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Frequency Therapeutics00303.00
Cassava Sciences00403.00

Frequency Therapeutics currently has a consensus target price of $37.00, suggesting a potential upside of 282.63%. Cassava Sciences has a consensus target price of $35.3333, suggesting a potential upside of 2.86%. Given Frequency Therapeutics' higher possible upside, research analysts plainly believe Frequency Therapeutics is more favorable than Cassava Sciences.

Profitability

This table compares Frequency Therapeutics and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Frequency Therapeutics-68.59%-12.56%-9.92%
Cassava SciencesN/A-22.01%-20.85%

Risk & Volatility

Frequency Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Earnings and Valuation

This table compares Frequency Therapeutics and Cassava Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Frequency Therapeutics$28.95 million11.42$-18,750,000.00($2.29)-4.22
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-128.52

Cassava Sciences has lower revenue, but higher earnings than Frequency Therapeutics. Cassava Sciences is trading at a lower price-to-earnings ratio than Frequency Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

57.5% of Frequency Therapeutics shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 15.4% of Frequency Therapeutics shares are held by insiders. Comparatively, 13.7% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Frequency Therapeutics beats Cassava Sciences on 7 of the 12 factors compared between the two stocks.

Frequency Therapeutics (NASDAQ:FREQ) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Frequency Therapeutics and Shattuck Labs, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Frequency Therapeutics00303.00
Shattuck Labs00603.00

Frequency Therapeutics currently has a consensus target price of $37.00, suggesting a potential upside of 282.63%. Shattuck Labs has a consensus target price of $45.60, suggesting a potential upside of 54.52%. Given Frequency Therapeutics' higher possible upside, research analysts plainly believe Frequency Therapeutics is more favorable than Shattuck Labs.

Profitability

This table compares Frequency Therapeutics and Shattuck Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Frequency Therapeutics-68.59%-12.56%-9.92%
Shattuck LabsN/AN/AN/A

Earnings and Valuation

This table compares Frequency Therapeutics and Shattuck Labs' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Frequency Therapeutics$28.95 million11.42$-18,750,000.00($2.29)-4.22
Shattuck LabsN/AN/AN/AN/AN/A

Shattuck Labs has lower revenue, but higher earnings than Frequency Therapeutics.

Institutional and Insider Ownership

57.5% of Frequency Therapeutics shares are held by institutional investors. 15.4% of Frequency Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Frequency Therapeutics (NASDAQ:FREQ) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Frequency Therapeutics and Zymeworks, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Frequency Therapeutics00303.00
Zymeworks03712.82

Frequency Therapeutics currently has a consensus target price of $37.00, suggesting a potential upside of 282.63%. Zymeworks has a consensus target price of $51.50, suggesting a potential upside of 89.76%. Given Frequency Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Frequency Therapeutics is more favorable than Zymeworks.

Profitability

This table compares Frequency Therapeutics and Zymeworks' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Frequency Therapeutics-68.59%-12.56%-9.92%
Zymeworks-569.13%-44.06%-34.36%

Risk & Volatility

Frequency Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Earnings and Valuation

This table compares Frequency Therapeutics and Zymeworks' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Frequency Therapeutics$28.95 million11.42$-18,750,000.00($2.29)-4.22
Zymeworks$29.54 million42.59$-145,440,000.00($3.83)-7.11

Frequency Therapeutics has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Frequency Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

57.5% of Frequency Therapeutics shares are held by institutional investors. Comparatively, 75.1% of Zymeworks shares are held by institutional investors. 15.4% of Frequency Therapeutics shares are held by insiders. Comparatively, 4.2% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Frequency Therapeutics beats Zymeworks on 8 of the 15 factors compared between the two stocks.

Frequency Therapeutics (NASDAQ:FREQ) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Frequency Therapeutics and Innoviva, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Frequency Therapeutics00303.00
Innoviva10001.00

Frequency Therapeutics currently has a consensus target price of $37.00, suggesting a potential upside of 282.63%. Innoviva has a consensus target price of $10.00, suggesting a potential downside of 16.94%. Given Frequency Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Frequency Therapeutics is more favorable than Innoviva.

Profitability

This table compares Frequency Therapeutics and Innoviva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Frequency Therapeutics-68.59%-12.56%-9.92%
Innoviva67.16%53.99%28.92%

Risk & Volatility

Frequency Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Earnings and Valuation

This table compares Frequency Therapeutics and Innoviva's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Frequency Therapeutics$28.95 million11.42$-18,750,000.00($2.29)-4.22
Innoviva$261.02 million4.67$157.29 million$1.438.41

Innoviva has higher revenue and earnings than Frequency Therapeutics. Frequency Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

57.5% of Frequency Therapeutics shares are held by institutional investors. Comparatively, 71.5% of Innoviva shares are held by institutional investors. 15.4% of Frequency Therapeutics shares are held by insiders. Comparatively, 0.3% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Innoviva beats Frequency Therapeutics on 8 of the 14 factors compared between the two stocks.

Frequency Therapeutics (NASDAQ:FREQ) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Institutional and Insider Ownership

57.5% of Frequency Therapeutics shares are held by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are held by institutional investors. 15.4% of Frequency Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Frequency Therapeutics and COMPASS Pathways, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Frequency Therapeutics00303.00
COMPASS Pathways00603.00

Frequency Therapeutics currently has a consensus target price of $37.00, suggesting a potential upside of 282.63%. COMPASS Pathways has a consensus target price of $70.75, suggesting a potential upside of 115.64%. Given Frequency Therapeutics' higher possible upside, research analysts plainly believe Frequency Therapeutics is more favorable than COMPASS Pathways.

Profitability

This table compares Frequency Therapeutics and COMPASS Pathways' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Frequency Therapeutics-68.59%-12.56%-9.92%
COMPASS PathwaysN/AN/AN/A

Earnings and Valuation

This table compares Frequency Therapeutics and COMPASS Pathways' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Frequency Therapeutics$28.95 million11.42$-18,750,000.00($2.29)-4.22
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A

Frequency Therapeutics has higher revenue and earnings than COMPASS Pathways.

Summary

Frequency Therapeutics beats COMPASS Pathways on 5 of the 9 factors compared between the two stocks.


Frequency Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Endo International logo
ENDP
Endo International
1.5$5.75+2.1%$1.30 billion$2.91 billion-8.46
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.70+7.3%$1.28 billionN/A-144.58Analyst Downgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$29.51+0.0%$1.23 billionN/A0.00Analyst Report
Insider Selling
Zymeworks logo
ZYME
Zymeworks
1.8$27.25+2.8%$1.22 billion$29.54 million-7.23News Coverage
Innoviva logo
INVA
Innoviva
1.4$12.03+0.4%$1.21 billion$261.02 million6.14News Coverage
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$32.81+1.6%$1.18 billionN/A0.00Analyst Upgrade
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$31.17+2.5%$1.18 billionN/A0.00Analyst Report
Insider Selling
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$27.53+3.3%$1.17 billion$230,000.00-12.80
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.93+4.6%$1.16 billion$59.70 million-199.30
Omeros logo
OMER
Omeros
1.2$19.03+2.5%$1.15 billion$111.81 million-8.00
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.81+1.1%$1.14 billionN/A-17.12
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.09+0.1%$1.14 billionN/A-8.78Analyst Report
Increase in Short Interest
News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.7$21.01+4.4%$1.13 billionN/A0.00Insider Selling
News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.31+3.5%$1.12 billion$4.23 million-8.55
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$36.82+3.9%$1.11 billionN/A-2.63
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.01+0.6%$1.10 billionN/A-6.76Upcoming Earnings
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.05+0.9%$1.10 billion$42.12 million-11.89
MannKind logo
MNKD
MannKind
1.4$4.47+5.4%$1.05 billion$63.04 million-21.28Increase in Short Interest
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$18.90+0.5%$1.05 billion$3.65 million-1.99
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$21.96+1.6%$1.03 billionN/A-8.10
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$51.97+1.7%$1.03 billion$122.47 million-28.55
NKTX
Nkarta
1.8$33.47+6.6%$1.02 billionN/A0.00
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.87+2.6%$1.02 billionN/A-6.54
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$9.22+3.0%$1.01 billion$35.22 million-6.73
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$29.62+4.9%$1.01 billion$57.05 million0.00Analyst Report
News Coverage
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.7$25.25+1.6%$1.01 billion$800.40 million23.82
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$28.30+8.2%$1.00 billionN/A0.00
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.73+0.5%$969.04 millionN/A-12.78
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.62+2.6%$962.90 million$20.79 million-12.97
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$22.52+0.7%$951.21 millionN/A-7.77Gap Up
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.47+2.5%$950.88 million$120,000.00-3.51Analyst Report
News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.68+0.8%$908.31 million$227.19 million46.33Analyst Downgrade
Prothena logo
PRTA
Prothena
2.3$22.69+0.7%$901.34 million$810,000.00-8.86
Radius Health logo
RDUS
Radius Health
1.3$19.11+0.1%$897.08 million$173.32 million-7.83News Coverage
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.28+0.3%$891.84 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.69+7.5%$880.65 million$23.96 million-16.42Earnings Announcement
Analyst Report
Analyst Revision
Merus logo
MRUS
Merus
1.6$23.13+4.6%$841.08 million$31.13 million-7.53Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.04+0.0%$836.47 millionN/A-10.10
Annexon logo
ANNX
Annexon
1.9$22.10+1.4%$831.08 millionN/A0.00
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.40+1.5%$817.41 million$322.36 million124.29
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$25.95+6.9%$816.46 millionN/A-24.03
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.19+1.6%$803.00 million$296.70 million47.33Analyst Revision
Ardelyx logo
ARDX
Ardelyx
1.6$7.91+2.0%$796.35 million$5.28 million-7.83Gap Down
Epizyme logo
EPZM
Epizyme
1.8$7.82+1.0%$787.82 million$23.80 million-3.51Analyst Report
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.14+1.5%$775.42 million$148.36 million-7.05
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.06+0.2%$771.33 millionN/A0.00Increase in Short Interest
Humanigen logo
HGEN
Humanigen
1.7$14.44+6.2%$724.15 millionN/A0.00Analyst Report
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.49+0.5%$708.58 million$40.89 million-3.27
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.02+2.8%$704.45 million$322.07 million-4.78Upcoming Earnings
Decrease in Short Interest
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.85+0.2%$689.77 million$252 million-2.13
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.